Experimental pancreatic cancer vaccine elicits durable immune responses in high-risk participants

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is often diagnosed at advanced stages and carries a low five-year survival rate.

Approximately 10% of cases are associated with hereditary predisposition caused by pathogenic mutations in specific cancer susceptibility genes that are passed down from parent to child.

The disease evolves over time from precursor lesions such as pancreatic intraepithelial neoplasia and intrapapillary mucinous neoplasms. ...